what we do?

Rooted in science

sourced worldwide

LianBio is a biotechnology company focused on bringing paradigm-shifting medicines to patients.

arrow-btn

Scroll to see more

arrow-btn

intro

Our Mission

LianBio’s mission is to catalyze the development and accelerate availability of paradigm-shifting medicines to patients in China and major Asian markets through partnerships that provide access to the best science-driven therapeutic discoveries.

Learn More

Pipeline

Our Future

We are focused on building out a pipeline based on disease relevance to our target markets and the ability to impact patients with transformative mechanisms and precision-based therapeutics. We select programs with a strong scientific basis and clinical data and collaborate with world-class partners across a diverse array of therapeutic areas.

Stay up to date

News & Events

November 19, 2020

Pfizer and LianBio Announce Strategic Collaboration to Expand Development of Novel Therapeutics in Greater China

arrow-btn

November 3, 2020

LianBio Announces Clearance to Initiate the Phase 3 PROOF Trial of Infigratinib in Patients with Locally Advanced or Metastatic Unresectable Cholangiocarcinoma with FGFR2 Gene Fusions in China

arrow-btn

October 29, 2020

LianBio Announces $310 Million Crossover Financing

arrow-btn

August 11, 2020

MyoKardia and LianBio Form Strategic Partnership to Develop and Commercialize Mavacamten Together in Greater China

arrow-btn
See All

We are here for you

Contact Us

Email us directly:

IR@LianBio.com careers@lianbio.com

Office Addresses

Shanghai Office
9th Floor, Kerry Parkside, 1155 Fangdian Road
Unit 901-902
Shanghai, PRC 201204

New Jersey Office
103 Carnegie Center Drive
Suite 215
Princeton, NJ 08540